Access cutting-edge scleroderma treatment through this clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.
Access scleroderma specialists in Iowa City at no cost
This study follows strict safety protocols and ethical guidelines
All study-related scleroderma treatment provided free
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Sponsor: Zura Bio Inc
Check if you qualify for this scleroderma clinical trial in Iowa City, IA
If you're searching for scleroderma treatment options in Iowa City, IA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Iowa City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced scleroderma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.